Crystalline form

WO2025008402A1PCT designated stage expired Publication Date: 2025-01-09SANOFI SA(FR) +1
View PDF 1 Cites 2 Cited by

Patent Information

Application Number
PCT/EP2024/068730
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-04
Filing Date
2024-07-03
Publication Date
2025-01-09

Smart Images

  • Figure EP2024068730_09012025_PF_FP_ABST
    Figure EP2024068730_09012025_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein is a crystalline form of a compound of Formula (I): i.e. (7R,14R)-11-[2-(1-aminocyclobutyl)pyrimidin-5-yl]-1-(difluoromethoxy)-6-methyl-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one. A pharmaceutical composition comprising the crystalline form, and medical uses of the crystalline form and pharmaceutical composition are also described.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Fused pentacyclic imidazole derivatives as modulators of TNF activity

    WO2018197503A1

Cited By

  • Modulators of TNF-alpha activity

    US12691095B2

  • Fused heterocyclic derivative and pharmaceutical use thereof

    WO2025247401A1